Plain-English translation of NCT03377699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 diabetes research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial examined whether a long-acting insulin called could safely help pregnant women with type 1 diabetes manage their blood sugar levels. Participants received either or —a similar long-acting insulin—along with a faster-acting insulin called that was taken multiple times throughout the day. Researchers monitored both mother and baby to see which treatment worked best and was safest during pregnancy.
Pregnancy significantly changes how the body uses insulin, and women with type 1 diabetes need very careful blood sugar control to protect both themselves and their growing babies. This trial was designed to determine if this newer medication could offer pregnant women a better or safer option for managing their diabetes.
Participants received pre-filled insulin pens and were randomly assigned to receive either or , both taken once daily along with the faster-acting taken multiple times per day. Throughout the study, which lasted between 10 and 25 months depending on whether they were already pregnant at enrollment, participants checked their blood sugar several times daily and attended regular clinic visits that included blood tests, urine samples, and ultrasound scans to monitor both their health and their baby's development.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Argentina